CGEN - Compugen signals leadership transition and advances COM701 ovarian cancer trial with interim data targeted for 2026
2025-08-07 06:30:57 ET
More on Compugen
- Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript
- Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Compugen
- Historical earnings data for Compugen
- Financial information for Compugen